

mol) of *p*-TosCl in 35 ml of pyridine. Stirring was continued for 0.5 hr after which the solvent was removed by distillation. The residue was partitioned between H₂O and Et₂O. The Et₂O layer crystallized to give 3.8 g of **12**. Evaporation of the mother liquor gave 3.5 g of mixture **13** which was not characterized. Two recrystallizations of **12** from EtOH afforded material which had mp 172–174°. *Anal.* (C₂₂H₂₉N₂O₃S) C, H, N.

cis-**1,2,3,4,4a,5,10,10a-Octahydro-5,5-dimethyl-1-(*p*-toluenesulfonyl)benzo[*g*]quinoline (14)**. **A.**—Compound **12** (2.8 g, 0.07 mol) was cyclized according to the procedure given above for the preparation of **9** and **10**. Crystallization of the crude residue from EtOH gave 2.2 g of **14**. Recrystallization from EtOH gave material, mp 143–145°. *Anal.* (C₂₂H₂₇N₂O₂S) C, H, N.

B.—Residue **13** (0.54 g, 0.0014 mol) was cyclized according to the above procedure to give 0.36 g of **14** identical with that prepared above.

Carbinols for Cyclization Studies.—These derivatives were prepared from the pure isomeric amino alcohols **8b**.² Reductive methylation with CH₂O and H₂ over Pd–C gave the NMe derivatives: *cis* isomer mp 94–96°, *Anal.* (C₁₇H₂₇NO) C, H, N; *trans* isomer mp 78–79°, *Anal.* (C₁₇H₂₇NO) C, H, N. Acylation with AcCl or *p*-O₂NC₆H₄SO₂Cl in CHCl₃ in the presence of Et₃N gave the corresponding amide: *cis*-*N*-acetyl, mp 138–141°, *Anal.* (C₁₈H₂₇NO₂) C, H, N; *trans*-*N*-acetyl, mp 111–113°, *Anal.* (C₁₈H₂₇NO₂) C, H, N; *cis*-*N*-*p*-O₂SC₆H₄NO₂, mp 182–186°, *Anal.* (C₂₂H₂₅N₂O₆S) C, H, N; *trans*-*p*-O₂SC₆H₄NO₂, mp 132–134°, *Anal.* (C₂₂H₂₅N₂O₆S) C, H, N. The *p*-C₆H₄NO₂ derivatives were prepared according to the procedure of Badar, et al.¹³ These compounds could not be obtained crystalline, and were characterized only by their ir spectra.

3-Isopropylidene-2-*p*-methoxybenzylpiperidine and Derivatives.—The neutral fraction from the decarbobenzoylation of 1-benzyloxy carbonyl-2-(*p*-methoxybenzyl)- α,α -dimethyl-3-piperidinemethanol was allowed to stand for 3 months. A 21.7-g sample of this residue was diluted to 200 ml total volume with EtOH and hydrogenated over Pd–C at room temperature and 4 atm. Uptake ceased after 3 hr with the consumption of ap-

proximately 1 molar equiv of H₂. The basic fraction was dissolved in dil HCl and cooled to give, after filtration and drying, 9.1 g of crude **23**·HCl. Recrystallization from EtOH–Et₂O gave pure **23**, mp 255–257°, nmr (CDCl₃, TMS) 413 (A₂B₂,4) 223 (s, 3), 95 (s, 3), 64 Hz (s, 3). *Anal.* (C₁₈H₂₄ClNO) C, H, N.

The NMe and *p*-SO₂C₆H₄NO₂ derivatives were prepared by the procedures indicated in the previous section and had the following properties: NMe·HCl, mp 179–183°, *Anal.* (C₁₇H₂₅ClNO) C, H, N; *N*-*p*-SO₂C₆H₄NO₂, mp 114–116°, *Anal.* (C₂₂H₂₆N₂O₅S) C, H, N.

Benzo[*g*]quinoline Derivatives as Nmr References.—The corresponding derivatives of *cis*- and *trans*-1,2,3,4,4a,5,10,10a-octahydro-5,5-dimethyl-7-methoxy-benzo[*g*]quinoline were prepared by the same procedures and the nmr spectra recorded. The compounds not previously reported had the following physical properties (the numbers in parentheses following the melting point are the chemical shifts in Hz of the *gem*-Me₂ groups in the 60 MHz nmr spectra): *cis*-*N*-*p*-C₆H₄NO₂, glass (80,79), *Anal.* (C₂₂H₁₈N₂O₃) C, calcd, H, 6.89, N, 7.67; found, H, 7.41, N, 8.60; *trans*-*N*-*p*-C₆H₄NO₂, mp 164–166° (83,70), *Anal.* (C₂₂H₂₆N₂O₃) C, H, calcd, N, 7.67; found, 9.04; *cis*-*N*-acetyl, mp 81–85° (80,78), *Anal.* (C₁₈H₂₃NO₂) C, H, calcd, N, 4.87; found 5.33; *trans*-*N*-acetyl, mp 157–159° (80,68), *Anal.* (C₁₈H₂₃NO₂) C, H, N; *cis*-*N*-*p*-SO₂C₆H₄NO₂, mp 159–161° (81,79), *Anal.* (C₂₂H₂₆N₂O₅S) C, H, N; *trans*-*N*-*p*-SO₂C₆H₄NO₂, mp 204–205° (79,59), *Anal.* (C₂₂H₂₆N₂O₅S) C, H, N.

Cyclization Procedure.—A solution of 100 ml of AcOH and 20 ml of H₂SO₄ was used for all cyclizations. A 125-mg sample of the carbinol and 1.0 ml of the acid were heated on a steam bath for 5 min, diluted with 25 ml of H₂O, made slightly basic with NH₄OH, and extracted with 25 ml of CHCl₃. The extract was dried, filtered, and concentrated and the entire residue used for nmr. The resulting spectrum was compared with that of the two pure products, and the relative amounts of each determined.

Acknowledgments.—The authors wish to thank Mr. K. D. Fleischer for elemental analyses, Dr. R. K. Kullnig for spectral data, and Mr. A. K. Pierson for pharmacological results.

(13) H. Bader, A. R. Hansen, and F. J. McCarty, *J. Org. Chem.*, **31**, 2319 (1966).

Novel Analgetics and Molecular Rearrangements in the Morphine–Thebaine Group. XVIII.¹

3-Deoxy-6,14-endo-etheno-6,7,8,14-tetrahydrooripavines

JOHN W. LEWIS AND MICHAEL J. READHEAD

Pharmaceutical Research Laboratories, Reckitt & Sons, Hull, England

Received November 10, 1969

7-Substituted 3-deoxy-6,14-endo-etheno-6,7,8,14-tetrahydrooripavines have been prepared by hydrogenolysis of the oripavine diethylphosphatyl esters. In some cases partial reduction of the etheno bridge also occurs. The deoxy compounds show analgetic potency intermediate between the oripavine and thebaine analogs.

The nature of the C₃ substituent is very important in determining analgetic potency in the morphine series (**1**).² Thus heroin (**1c**) is more potent than morphine (**1a**) which is itself considerably more potent than codeine (**1b**). In the related series of analgetics (**3b–6b**) derived from 6,14-endo-ethenotetrahydrooripavine the effect of removing the phenolic hydroxyl group by hydrogenolysis with Na in liquid NH₃ of the diethyl phosphate derivatives (**2**)³ has now been investigated.

The phosphates were prepared by reaction of the oripavine derivatives with diethyl phosphite and CCl₄ and were dissolved in Et₂O for the Na–liquid NH₃ re-

action. In most cases the hydrogenolysis reaction went to completion but purification of the products was not always easy. In the case of the 7-dimethylcarbinol (**3c**) a by-product having similar chemical and physical properties was isolated by preparative tlc. This was shown to be identical with the 3-deoxy compound (**8c**) derived from the 6,14-endo-ethanooripavine (**8b**). Hydrogenation of the olefinic bond by Na in liquid NH₃ was surprising in view of the fact that **3a** is catalytically hydrogenated only with difficulty,⁴ and reduction of disubstituted olefins by metal–amine systems occurs only with the powerful Li–alkylamine reagents.⁵ The

(1) Part XVII: J. W. Lewis and W. I. Rushworth, *J. Chem. Soc. C*, 560 (1970).

(2) N. B. Fildes, H. H. G. O'Neil, and G. J. P. Ross, *J. Pharm. Med. Chem. Ther.*, 1969, 117.

(4) K. W. Bentley, D. G. Hardy, and B. Meek, *J. Amer. Chem. Soc.*, **89**, 5778 (1967).


TABLE I

Structure	N substituent	Analgetic potency (tail pressure test), morphine = 1		
		3-H	3-OH	3 OMe
3	Me	6	25	4.2
4	Me	100	1100	16
5	Me	280	2800	40
6	Me	<0.02	20	0.04
7	Me	2000	1600	110
8	Me	13	70	2.8
9	CPM	0.02 ^a	100 ^a	0.07 ^a
10	Allyl	<0.02	2.2 ^a	0.02
11	Allyl	1.9	20	0.75
12	CPM	0.11	35 ^a	0.4 ^a
13	CPM	0.9	70 ^a	0.2
14	CPM	5.0	48	3.8
15	Me	1.2	42	0.4

^a Potency as morphine antagonist in tail pressure test (ualorphine = 1).

phenylmethyl carbinol **6c** also underwent partial hydrogenation of the etheno bridge when the phosphate ester was hydrogenolyzed. Surprisingly the C₇ ethyl derivative **15c** having a more accessible etheno bridge did not suffer partial hydrogenation.


Oripavines **10b-14b** in which the N-substituent is allyl or cyclopropylmethyl were converted into 3-deoxy compounds without affecting the N-substituent but the etheno bridge in **12c** underwent partial hydrogenation.




- a. R¹ = R² = H
 b. R¹ = Me; R² = H
 c. R¹ = R² = Ac

Structure-Activity Relationships.—Table I shows the analgetic and morphine-antagonist potencies of the deoxy compounds compared with the corresponding

3-methoxy and 3-hydroxy analogs. The *N*-methyl deoxy compounds are more potent analgetics than the thebaine analogs (3-OMe) but less potent than the oripavines (3-OH). An exception is the phenethylcarbinol **7c** which is 2000 times more potent than morphine, somewhat greater than the corresponding oripavine **7b**. Where the *N*-allyl and *N*-cyclopropyl-



3. R² = Me
 4. R² = Pr
 5. R² = *n*-Pentyl
 6. R² = Ph
 7. R² = Phenethyl



10. R² = Me; R³ = allyl
 11. R² = *n*-Pr; R³ = allyl
 12. R² = Me; R³ = CPM
 13. R² = Et; R³ = CPM
 14. R² = *iso*-Pentyl; R³ = CPM

- a. R¹ = OMe
 b. R¹ = OH
 c. R¹ = H

^aCPM = cyclopropylmethyl

methyl oripavines are morphine antagonists the derived deoxy compounds show much weaker antagonist character and, in most cases, pronounced analgetic activity. On the other hand the potency of the *N*-substituted oripavine analgetics is considerably greater

TABLE II

No.	Crystallization solvent ^a	Mp, °C	Yield, %	Formula	Analyses
3c	A	196-197	42 ^d	C ₂₃ H ₂₉ NO ₃	C, H, N
4c	B	207-209	37	C ₂₃ H ₃₃ NO ₃	C, H, N
5c	A	134-135	47	C ₂₇ H ₃₇ NO ₃	C, H, N
6c	B	253-255	26	C ₂₃ H ₃₁ NO ₃	C, H, N
7c	C	157-159	58	C ₃₀ H ₃₉ NO ₃	C, H, N
8c	C	174-176	58	C ₂₃ H ₃₁ NO ₃	C, H, N
9c	D	245-250	43	C ₂₆ H ₃₆ ClNO ₃ · 0.5H ₂ O ^f	C, H, Cl, N
10c	A	140-141	38	C ₂₃ H ₃₁ NO ₃	C, H, N
11c	B	129-130	25	C ₂₇ H ₃₅ NO ₃	C, H, N
12c	A	135-136	61 ^b	C ₂₆ H ₃₆ NO ₃	C, H, N
13c	B	230-235	54	C ₂₇ H ₃₆ ClNO ₃ ^f	C, H, Cl, N
14c	B	143-146	37	C ₃₀ H ₄₁ NO ₃	C, H, N
15c	C	125-127	35	C ₂₉ H ₂₇ NO ₂	C, H, N

^a A, EtOH-H₂O; B, EtOH; C, MeOH; D, Et₂O. ^b Based on oripavine. ^c C: calcd, 75.91; found, 75.3. ^d C: calcd, 78.74; found

than that of the deoxy derivatives. The corresponding thebaine derivatives have profiles similar to the deoxy compounds but with less analgetic character.

Experimental Section

Melting points were determined on a Kofler hot-plate and are uncorrected. Where analyses are indicated only by symbols of the elements the results obtained for those elements were within $\pm 0.4\%$ of the theoretical values. The structures of all compounds were assigned on the basis of compatible ir and nmr spectra. See Table II for experimental data.

6,14-endo-Etheno-7 α -ethyltetrahydrooripavine 3O-Diethyl Phosphate.—Et₃N (5 ml) was added slowly with vigorous shaking to an ice-cold mixture of 6,14-endo-etheno-7 α -ethyltetrahydrooripavine⁶ (10.8 g), CCl₄ (10 ml), and diethyl phosphite (4.5 ml). The mixture was set aside at room temperature for 18 hr. The mixture was diluted with H₂O and the organic layer separated. The aqueous solution was extracted with CHCl₃. The combined organic solutions were washed several times with 1 N NaOH and finally H₂O. The dried (Na₂SO₄) extract was evaporated and the residue recrystallized (C₆H₆-petroleum ether) to give 7.0 g (47%) of the phosphate, mp 135–137°. *Anal.* (C₂₆H₃₆NO₃P) C, H, N.

(6) K. W. Bentley, D. G. Hardy, J. W. Lewis, M. J. Readhead, and W. I. Rushworth, *J. Chem. Soc. C*, 826 (1969).

The phosphates of the other oripavine derivatives⁷ were prepared by analogous procedures and were hydrogenolyzed without purification.

General Procedure for the Hydrogenolysis of the Oripavine Phosphates.—The crude phosphate was dissolved in Et₂O and NH₃ was added (20 ml/g of phosphate); to the mixture Na (2 g-atoms) was added in small pieces, as rapidly as frothing would allow. EtOH (2 mol) was then added and the NH₃ allowed to evaporate. The residue was treated with H₂O and extracted with Et₂O. The combined ethereal extracts were dried (Na₂SO₄) and evaporated. Crystallization of the residue gave the 3-deoxyoripavine.

Biological Methods.—Analgetic activity was determined subcutaneously in the rat tail pressure test of Green and Young⁸ and morphine antagonism by the method of Green, Ruffell, and Walton.⁹

Acknowledgments.—The authors thank Mr. Michael Smith for assistance with synthesis, Mr. Cyril Young for preparative tlc, and Dr. Alan L. A. Boura for the pharmacological results.

(7) K. W. Bentley and D. G. Hardy, *J. Amer. Chem. Soc.*, **89**, 3281 (1967).

(8) A. F. Green and P. A. Young, *Brit. J. Pharmacol. Chemother.*, **6**, 572 (1951).

(9) A. F. Green, G. K. Ruffell, and E. Walton, *J. Pharm. Pharmacol.*, **6**, 390 (1954).

Central Nervous System Stimulants of the Xanthone Group


P. DA RE, L. SAGRAMORA, V. MANCINI, P. VALENTI, AND L. CIMA

Department of Chemistry, University of Pisa, Pisa, and Department of Pharmacology, University of Padua, Padua, Italy

Received October 17, 1969

A series of basic derivatives of methoxy-, hydroxy-, and chloroxanthones were synthesized and tested pharmacologically. Some N-disubstituted 4-aminomethyl-3-methoxyxanthones show a powerful CNS stimulating activity. Structure-activity relationships have been examined.

In continuation of our researches^{1,2,3} on CNS stimulating drugs of the benzopyrone series, the most significant of which is 3-methyl-7-methoxy-8-dimethylaminomethylflavone (dimefine, I), the xanthone analogs II have now been synthesized.



This modification of structure I was an outcome of our previous work and was made with the purpose of devising a drug which would reduce some undesirable side effects (such as the excitatory cortical component of the analeptic activity) as well as the toxicity and at the same time improve the clinical safety. The new carrier moiety of the CH₂NR₂ group was to permit a better insight into the structure-activity relationships and to make use of synthetic methods such as addition reactions and partial or total reduction of the CO group, which are more difficult to perform with chromone or flavone analogs.

(1) P. Da Re, L. Verlicchi, I. Setnikar, W. Murmann, and M. J. Magistretti, *Nature*, **184**, 362 (1959).

(2) I. Setnikar, W. Murmann, M. J. Magistretti, P. Da Re, and I.

The present work concerns some N-disubstituted 4-aminomethyl derivatives of 3-methoxyxanthone, selected on the basis of previous results² in the benzo- γ -pyrone series, as well as the corresponding derivatives of 3-methoxy-6-chloroxanthone, which were prepared in order to take advantage of the possible widening of the safety margin induced by the introduction of Cl.⁴ Furthermore, owing to the symmetry of the xanthone molecule we had the opportunity to prepare the bis(aminomethyl) derivatives of 3,6-dihydroxy- and 3,6-dimethoxyxanthone and so to verify the so-called molecular doubling principle,⁵ by which one could expect an inversion of the previously observed activity.

A few papers concerning the same subject (preparation of Mannich bases of hydroxyxanthones and alkylated xanthones) have appeared,^{6,7,8} but no biological data have been reported. These compounds however, on the basis of our previous findings,² ought to be less active than the MeO analogs.

We also wish to report an attempt to apply the

(4) A. Burger, "Medicinal Chemistry," 2nd ed., Interscience Publishers Inc., New York, N. Y., 1960, p 43.

(5) A. Lespagnol, *Actual. Pharmacol.*, **6**, 115 (1953).

(6) A. Mustafa, M. M. Sidky, and F. M. Soliman, *Can. J. Chem.*, **41**, 1731 (1963).

(7) Y. S. Agasimundin and S. Rajagopal, *J. Indian Chem. Soc.*, **41**, 471 (1963).